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Hypersensitivity pneumonitis (HP) also called exogenous allergic alveolitis = extrinsic allergic alveolitis in children is
an uncommon condition and may not be recognized and treated appropriately.
To assess current means of diagnosis and therapy and compare this to recommendations, we used the Surveillance
Unit for Rare Paediatric Disorders (ESPED) to identify incident cases of HP in Germany during 2005/6. In addition,
cases of HP reported for reference from all over Germany to our center in the consecutive year were included.
Twenty-three children with confirmed pediatric HP were identified. All (age 9.4 y (4.4-15.1) presented with dyspnoea
at rest or with exercise, mean FVC was 39% of predicted, seven of the 23 children already had a chronic disease
state at presentation. IgG against bird was elevated in 20, and against fungi in 15. Bronchoalveolar lavage was done
in 18 subjects (41% lymphocytes, CD4/CD8 1.99), and lung biopsy in 6. Except 2, all children were treated with
prolonged courses of systemic steroids. Outcome was not favourable in all cases.
Late diagnosis in up to a quarter of the children with HP and inappropriate steroid treatment must be overcome to
improve management of HP. Inclusion of children with HP into international, web-based registry studies will help to
study and follow up such rare lung diseases.
Keywords: Biopsy, Bronchoalveolar lavage, Children, Diffuse parenchymal lung diseases, Exogenous allergic
alveolitis = extrinsic allergic alveolitis, Precipitins, Steroid treatmentIntroduction
Hypersensitivity pneumonitis (HP) - in Europe called ex-
trinsic or exogenous allergic alveolitis (EAA) - is a complex
syndrome incited by numerous inhaled agents including
agricultural dusts, bio-aerosols, fungal-, bacterial- or proto-
zoan microorganisms, and certain reactive chemicals. In
children it is a relatively uncommon condition and the two
major inciting allergens are bird (avian) allergens including
down and inhaled particles derived from fungi, like
thermophilic actinomycetes, or rarely fusarium [1], aureo-
basidium [2,3] and epicoccum [4].
A previous NHLBI/ORD Workshop has summarized
state of the art and the needs and opportunities for research
in HP [5]. It was stated that because pediatric cases of HP
are rarely recognized or reported, knowledge is limited and* Correspondence: Matthias.griese@med.uni-muenchen.de
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reproduction in any medium, provided the oris based mostly on case reports and small series of patients.
Between 1960 and 2005, 95 cases of HP in children have
been reported in the literature [6-8]. In contrast to the data
from adults, 95% of the cases were males and 25% had a
family history of HP [5]. This hints to some reporting bias.
The finding of clubbing in 31% (10/32) of the children, sug-
gested that in the past the disease was recognized late in its
clinical course. Importantly, as deaths from HP have been
reported in children as well as adults [5,6], treatment may
be more difficult than anticipated. This is highlighted by
the fact that 3% of the children were not treated with remo-
val from the exposure. Also, treatment with corticosteroids
is very controversial. In addition to oral long term therapy
most frequently done (about 66%) [5], methylprednisolone
pulse therapy [9,10] or inhaled budesonide [11] were sug-
gested. Current recommendations in adults, as well as our
personal practice in children, clearly suggest no steroid
treatment at all, if possible [12].
Due to its rarity, many paediatricians and general practi-
tioners are likely not to be very familiar with the clinicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pulmonologists may not use up to date treatment. All
these issues, including an unknown proportion of cases of
interstitial lung disease in children which may represent
undiagnosed HP, suggested that current information on
the diagnosis and treatment of HP is warranted. We used
a survey that we performed to determine the incidence of
pediatric diffuse parenchymal lung diseases in Germany,
to learn more about the current status of HP in children
in Germany [13]. The goal of this study was to assess
current means of diagnosis and therapy of HP, to compare
this to the recommendations and to propose ways to
improve future management with the help innovative
strategies for rare lung diseases.
Methods
Study subjects and study design
The German Surveillance Unit for Rare Paediatric Disorders
[Erhebungseinheit für seltene pädiatrische Erkrankungen in
Deutschland (ESPED)] sends out monthly inquiries to all
paediatric hospitals, to report specific conditions inves-
tigated prospectively. We used this system from 2005 to
2006 to monitor interstitial lung diseases [13]; the number
of children under 17 years of age under surveillance was
14 393 400. The overall return rate was 97%, in case of a
positive reply, a detailed questionnaire was sent to the
reporting institution. We identified 11 children with HP
during this 2 year period. 12 additional children who were
reported to us for reference in the following year 2007
from all over Germany were also included. Only newly
diagnosed cases of pediatric HP were eligible for the study.
The main study objective was to describe current diagno-
sis and treatment of HP and to compare this practice to
recommendations [12]. The surveillance study and the
retrospective analysis of the children with HP were
approved by the local ethical committee (EK 355/04 and
letter 2010-3-5) and written informed consent of the
subjects and parents or legal guardians was obtained.
The surveillance study was prospective; retrieval of
detailed information on verified cases was retrospective.
Clinical information at diagnosis and from follow –up
was collected from all subjects. Of the 23, 22 were old
enough for lung function measurements, 17 underwent
bronchoscopy including BAL with cytology, and 13 chest
CTs were done. Diagnostic open lung biopsies were
done in 6 of the patients. None of the patients were
treated with systemic corticosteroids therapy at the time
of the diagnosis. All children had definite diagnosis of
HP, based on the criteria proposed by Schuyler et al.
1997 [14].
Serum and bronchoalveolar lavage fluid analysis
In all children serum IgG level for fungal and bird allergens
and in 17 children mycoplasma serology were determinedand the results judged as normal or increased according to
the appropriate lab reference values. BAL was performed
during flexible bronchoscopy. Lavage sites were middle or
lower lobes with no preference for radiological more af-
fected areas. Four times 1 ml per kg body weight of sterile
0.9% saline solution were instilled and then aspired [15].
The pooled fluid from 2nd to 4th aspirations were processed
for differential cell counts, and stained according to May-
Grünwald. In 7 children CD4+ and CD8+ lymphocytes
were determined by flow cytometric investigation.
Chest x-ray and CT scoring
We evaluated the radiographs and computed topogra-
phies (CT) of the chest from each patient independently
and blinded, knowing nothing about the patients, the
severity of their diseases, and the chronological sequen-
ces of the images. First we assessed the quality of the
scans and differentiated between high-resolution and
multi-slice CT examinations with or without contrast
medium. Afterwards we evaluated on both modalities, if
the hilar lymph nodes were enlarged (yes/no). Then we
divided each lung into three parts. The apical zone was
defined as the area from the apex of the lung to the
tracheal bifurcation, the middle zone from the tracheal
bifurcation to the lower pulmonary vein, and the inferior
zone from the lower pulmonary vein to the diaphragm.
For each zone on both sides we evaluated on every plain
film as well as on each CT scan different pathologies
with a scoring system. “0” meant, the pathology was
absent, “1” represented mild changes, “2” stood for
medium abnormalities, and “3” for massive findings. We
scored presence and extent of linear, reticular, or nodu-
lar patterns, cysts, bronchiectasis, ground glass opacities,
emphysema, and consolidations. The pathologies were
defined according to the Fleischner society [16].
Lung biopsy
Individual slides of all surgical lung biopsy specimens
were stained with hematoxylin and eosin, Prussian blue
(iron stain), Periodic acid-Schiff reaction (PAS) stain
(Glycogen, neutral mucopolysaccharides), and van Gieson’s
Stain (which demonstrates differential staining of collageni-
zed connective tissue, smooth muscle and elastic tissue)
and were assessed in a blinded manner by a pediatric path-
ologist (FB). Furthermore, immunohistochemical stains for
T-lymphocytes (CD3), B-lymphocytes (CD20), and macro-
phages (CD68) were performed.
Diagnosis of HP
The diagnostic criteria for HP included a known expo-
sure to an offending antigen, the presence of specific
IgG antibodies in serum against the identified antigen,
compatible clinical, radiographic, or physiologic findings,
a bronchoalveolar lavage (BAL) with lymphocytosis and
Table 1 Baseline data of the 23 children with
hypersensitivity pneumonitis included into the study
Sex 9 male of 23 total
Age at 1st visit (y) 9.8 ± 3
Time to diagnosis (mon) 1.3 ± 1
Initial presentation
Chronic cough, dyspnoea
at rest, cyanosis, clubbing
15, 13, 11, 3 of 23
Loss of weight per week
until diagnosis (kg)
- 0.73 ± 0.49
Non-pulmonary diagnoses Atopic eczema (2), Diabetes mellitus
Type I (1), hyperthyreoiditis, adipositas
(4), house dust mite allergy (2), bronchial
asthma (1), celiac disease (2), small
stature (1), hypothyroidism (1), alopecia
areata (1), enuresis nocturna (1), vitiligo
(1), GERD and nissen fundoplication (1)
Serum measurements
Elevated fungus IgG 17 of 23
Elevated bird IgG 21 of 23
Total IgG (fold upper limit) 1.2 ± 0.6
LDH i. S. (U/l) 352 ± 189
ACE i. S.(U/l) 53 ± 31
Positive serology for
mycoplasma
9 of 17 assessed
Bronchoalveolar lavage
measurements
Done in 17 children
Total cell count (/μl) 8800 ± 11017
Macrophages (%) 41 ± 25
Lymphocytes (%) 46 ± 26
Neutrophils (%) 13 ± 13
Eosinophils (%) 2.6 ± 2.1
CD4+/CD8+ (% Lymph) 36 ± 16/48 ± 25
CD4/CD8 Ratio 2.0 ± 2.8
Cultured bacteria None




Done in 22 children
FEV1 (% pred) 44 ± 21
FVC (% pred) 38 ± 15
MEF25 (% pred) 62 ± 45
DLCOcHb (% pred) 52 ± 28
SaO2 (%) Rest/excercise 93 ± 27/83 ± 40
pO2 (mmHg) Rest/excercise 64 ± 34/57 ± 20
pCO2 (mmHg) Rest/excercise 38 ± 20/34 ± 12
Lung biopsy Done in 6 children
Data are given as absolute numbers or mean ± SD.
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non-caseating granulomas or mononuclear cell infiltrates.
Statistical analysis
The results are reported as mean ± standard deviation
(SD) or frequencies of patients expressing a particular
feature or not. For comparison of the frequencies the
Fisher exact test was used. A two sided p-value of < 0.05
was considered significant. All individual data are available
in the Additional file 1.
Results
Clinical presentation
During a period of 3 years 23 cases in children with the
confirmed diagnosis of HP were collected from all over
Germany. Mean age at diagnosis was 10 y. The children
presented with acute (a, n = 6; symptoms prompted
assessments within days to one week), subacute (s, n = 8;
symptoms for at least one week, but less than 4 weeks
duration), and chronic (c, n = 9, symptoms for longer
than 1 month) disease expression. The time to diagnosis
after presentation to a physician was brief, however 3 of
23 children already had clubbing, suggesting that in some
cases it may have taken more time to see a physician. The
children were generally sick, with chronic cough, dys-
pnoea at rest, cyanosis, and a significant weight loss of up
to 3 to 4 kg of body weight. The responsible antigen by
history were bird or downy feathers alone in 16 of 23
cases, fungus alone in 3 of the 23 cases, both in 3 cases
and in one the antigen could not be suggested from
history (Table 1 and Additional file 1: Table S1).
Laboratory results
In contrast to the type of exposure obtained from his-
tory, 15 children had elevated IgG antibodies against
both, fungus and birds or downy feathers. Only 5 of the
15 children with a history suggestive of a reaction
against birds or downy feathers had only these anti-
bodies, and only 1 of the 3 with a history suggestive of
fungus, had solely antibodies against fungus. Thus the
specificity of elevated IgG antibodies is very low (Table 1
and Additional file 1: Table S2). Total serum IgG was
not significantly elevated (expected mean 1.0, actual mean
1.18; discrepancy −0.18, 95% CI of discrepancy −0.026 to
0.38, P = 0.08, one sample t test). Of interest, in 16 of 23
children an atypical pneumonia was suspected and treated
with macrolides or tetracycline, serology was positive for
mycoplasma in 9 of 17 children tested, whereas PCR in
BAL was negative in all tested cases.
BAL results
Total cell count was elevated in some, but not all cases,
whereas the cell differential showed a lymphocytosis in
91% (21 of 23). In 2 children neutrophilia was dominant,indicating the acute phase; in one of these lung biopsy con-
firmed the diagnosis of HP (Additional file 1: Table S3).
The ratio of CD4/CD8 positive lymphocytes was elevated
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known scatter [8].
Lung function
All children had a severely restricted lung function at
diagnosis (average FVC 38% of predicted), a reduced
diffusion capacity for CO and a marked desaturation on
exercise, however were normocapnic (Additional file 1:
Table S4).
Radiology
96% of the CT scans showed characteristic nodular opaci-
ties, 75% linear opacities, and 73% a ground glass pattern
with increased attenuation (Figure 1). Except for reticular
opacities which were present in 63% of all cases, other
abnormalities were much less frequent (Table 2). The
chest x-rays were scored first and in a blinded manner.
Unexpected the frequency of the abnormalities were
comparable to those scored on the CT scans.
Histology
In 6 of 23 children an open lung biopsy was done, as
the diagnosis was not made on clinical and radiological
grounds. Average age of diagnosis was not significantlyFigure 1 HRCT findings of HP. Upper panel shows acute HP with
ground-glass opacification more prominent on the right side, the
lower panel shows diffuse micronodules and ground-glass
attenuation in subacute HP.lower than in the other children (Additional file 1:
Table S3). In all patients, a mild to strong inflammation
was found. Alveolar septal spaces were thickened by
increased amounts of lymphocytes (Figure 2A) mainly
T-lymphocytes (Figure 2C). Alveoli were variably filled
with lymphocytes (Figure 2A), which were mainly T-
lymphocytes (Figure 2E) and macrophages (Figure 2D).
In three out of six cases loosely formed non-caseating
histiocytic granulomas with multinucleated histiocytic
giant cells (Figure 2B) were found. Furthermore a mild to
strong bronchiolitis (Figure 2A) with many lymphocytes
(mainly T-lymphocytes (Figure 2E)) and lymph follicles
(mainly B-lymphocytes (Figure 2F)) in the bronchiolar
wall as well as and many intraepithelial lymphocytes
(mainly T-lymphocytes (Figure 2E)) was found.
Treatment and outcome
All children but one were hospitalized for prolonged
times, the average stay being 16 days. During this time
all except 3 of the 23 children, were treated with sys-
temic steroids. Only two centers did not use steroids
(Table 3 and Additional file 1: Table S5). The systemic
steroids were tapered over prolonged periods, on average
given for almost 4 months. About 50% of the children in
addition received inhaled corticosteroids. Of interest,
even initial allergen avoidance was not strict in all chil-
dren. In these, as well as in those children with allergen
re-exposure, a prolonged course was observed and in
one child the course worsened during the follow up of
about 1 year after the initial diagnosis.
Discussion
From this work 3 main conclusions can be derived; (1)
diagnosis of pediatric HP is frequently late, despite charac-
teristic symptoms at presentation, (2) allergen avoidance
as the principal treatment is not always followed very
strictly, and (3) prolonged and high dose steroid treatment
is often used.
Although HP is the most frequent chronic interstitial
lung disease in children [13], a quarter of the children
with HP presented here and incident during a 3 y period
in Germany, were diagnosed in chronic disease state.
This together with the fact that lung biopsies were done
at a relatively high frequency, suggests that some diffi-
culties have to be overcome to diagnose this condition
in childhood. All children, except one who was not mea-
sured, but was hypoxemic at rest (O2-saturation 80%),
presented with a severely (≤65% pred.) restricted lung
function and almost all had reduced oxygen saturation
at rest or with exercise (Additional file 1: Table S3).
These findings are very characteristic for presenting HP
[17], nevertheless in 70% of the children an atypical
pneumonia was diagnosed and empiric antibiotic treat-
ment was started. Lung biopsy helped in all 6 instances
Table 2 Results of blinded, independent scoring by two specialized radiologists of 30 chest x rays films taken in 16
children and 13 CT scans taken in 13 different children
Chest x-ray (p.a.) Chest CT
Abnormality present Yes/total scored % positive (mean (range)) Yes/total scored % positive (mean (range))
Hilar lymph nodes 6/30 20 (0–23) 2/13 12 (8–15)
Linear opacities 29/30 75 (53–97) 11/13 75 (65–85)
Reticular opacities 29/30 91 (85–97) 10/13 63 (50–77)
Nodular opacities 28/30 83 (73–93) 13/13 96 (92–100)
Cystic opacities 1/30 3 (2–3) 0/13 0 (0)
Bronchiectasis 5/30 10 (3–17) 1/13 8 (8–15)
Ground glass pattern, increased attenuation 24/30 72 (63–80) 10/13 73 (69–77)
Emphysema, reduced attenuation 0/30 0 (0) 0/13 0 (0)
Consolidation 4/30 12 (10–13) 0/13 10 (0–19)
The quality of the CT scans was judged as good in 9 cases, moderate in 3 and poor in 1. All were inspiratory scans, in four contrast medium was used, in six high
resolution scans were available.
Figure 2 The 3 typical findings of HP are 1. bronchiolitis, 2. alveolitis and 3. loosely formed non-caseating histiocytic granulomas. (A)
shows bronchiolitis (B) with lymph follicles (L) and increased amounts of lymphocytes in the walls of the bronchiole and alveolitis (+). Figure 2(B)
depicts a typical granuloma (arrows) with multinucleated histiocytic giant cells (*). Immune histochemical stains for CD 3 confirm the presence of
increased amounts of T cells in the alveoli (asterix) and septi (arrow) (C), and stains CD68 the presence of macrophages in the alveoli (asterisk)
(D). (E) demonstrates intraepithelial T lymphocytes in the bronchial epithelium and (F) aggregates of B lymphocytes (lymph follicles). Single
scattered B lymphocytes were also found in alveolar septa and alveoli. Magnification is indicated by bar in each figure.
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Table 3 Treatment and follow up of the 23 children with
hypersensitivity pneumonitis included into the study
Empiric antibiotic therapy for suspected atypical
pneumonia, response to this therapy
16 of 23 and
3 of 16
Allergen avoidance recommended and definitely
eliminated
18 of 23
Initial stay in hospital (days) 16 ± 12
Systemic steroids 20 of 23
Dose of Prednisolone (mg/kg KG) 2 ± 0.5
Duration of taper (d) 119 ± 85
Inhaled steroids 11 of 23
Dose of budesonide equivalents (μg/d) 427 ± 271




Follow up time (years) 1.1 ± 1.0
Data are given as absolute numbers or mean ± SD.
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showed in all cases variable mural and luminal lym-
phocytic alveolitis as well as bronchiolitis, whereas
loosely formed non-caseating histiocytic granulomata
with multinucleated giant cells where found only in
three cases; although in retrospect, diagnosis might have
been possible from the combination of characteristic clin-
ical features including the presence of serum precipitins,
BAL lymphocytosis (except for 1 case), and FVC below
50% pred.
CT scans have recently been demonstrated to signifi-
cantly contribute to the initial diagnosis of HP in adults,
with specificity of 81% [5]. Their value in children has
not yet been demonstrated. In this series in only 13 of
23 children CT’s were done, i.e. a diagnosis was reached
in more than 40% without a CT scan. In addition, a
review of the CT scans obtained demonstrated studies of
variable quality. Only 9 of 13 cases with CT had a quality
judged as good, and the quality was moderate in 3 and
poor in 1. Major reasons for the failure were artifacts from
respiratory motion. As already proposed for adults, these
results highlight the need for and compliance with
standardized protocols [18]. The characteristic radiologic
features known from adult cases of HP were seen in these
pediatric patients to similar extents [19]. Of interest was
the high degree of concordance in the frequency of abnor-
mal chest radiograph and CT findings. However it must
be cautioned as only the chest CT findings “are charac-
teristic” of HP.
The overwhelming majority of HP in the pediatric
population is due to bird and fungus allergens; one of the
challenges may be to identify alternative sources of these
allergens, like fungus contaminated indoor hydroponics[3], misting fountains [20], basement showers [4] or
possibly even wild city pigeons [21]. Up to 25% of the
cases reported previously in the pediatric literature [5]
and few additional case reports [2,3,22] were “familial”
cases. Reasons may include (1) publication bias from pre-
ferring familial cases; (2) insensitivity of history to detect
alone standing early disease, or (3) a higher likelihood for
serologic testing in families with affected other members.
Although common genetic predisposing factors may also
be involved, they have not been demonstrated by now.
Familiarity in the context of HP is most likely due to a
common exposition to the antigens.
Identification of the responsible allergen is critical for
avoidance and the causal and principal treatment [12].
Of interest, almost all children identified here were
treated with systemic steroids. The advantage of such an
approach is a more rapid therapeutic response with ster-
oid treatment; however this introduces the impossibility
to monitor the completeness of allergen avoidance mea-
sures. Lack of antigen avoidance and non-effectiveness
of corticosteroid therapy results in pulmonary fibrosis
and end-stage lung disease with death [23] or the need
of lung transplant at young age [24]. Thus for treatment
primarily careful allergen avoidance with associated
clinical improvement is warranted. This proposition
needs to be tested in a randomized controlled trial using
steroids or placebo.
A weakness of the study may be that we recovered
most, but not all incident cases, as one, published as a
single case, and came to our attention during manu-
script preparation [3]. Secondly, it is possible that some
chronic forms might have been misdiagnosed as severe,
steroid-resistant asthma [21]. Although there was a very
high preponderance of male children (95%) in the pedia-
tric cases reported until 2005 [5], evened out sex ratios
were demonstrated recently in a population based study
[25]. Therefore the male to female ratio of 9/14 found in
the present study, suggests an almost homogenous
sampling. Lastly, long term follow up was not possible
with the design of the study, based on the German
Surveillance Unit which is not prepared for longitudinal
follow up. This can be achieved with register studies.
Among the strengths of the study is the relatively large
cohort of contemporary and newly detected pediatric
HP cases collected over a brief period of time. The ob-
served current approach to diagnosis and therapy clearly
demonstrates that the index of suspicion for HP needs
to be increased substantially and that an early diagno-
sis must be established by much more quality con-
trolled assessment of the clinical, radiological and
laboratory findings. In particular, allergen avoidance is
key for management. The role of corticoids which are
generally used needs to be defined in prospective
clinical trials.
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an international study of this rare entity. Capture and
long term follow up of the widely scattered cases of HP
in children occurring in remote places can be easily
overcome by web-based studies within rare disease
registries (www.kids-lung-register.eu). As such, the
recently funded proposal “Orphans Unite: chILD better
together – European Management Platform for Childhood
Interstitial Lung Diseases” (www.childeu.net) under the
FP7 program will provide an excellent base for this
important task.
Additional file
Additional file 1: Table S1. Clinical presentation of the children.
Table S2. Serum laboratory results. Table S3. Bronchoalveolar lavage
and lung biopsy results. Table S4. Lung function. Table S5. Treatment
and outcome.
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